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Abstract
Background: Obsessive-compulsive disorder (OCD) is a relatively common and disabling psychiatric disorder whose
pathophysiology is incompletely understood. In this study, we utilized magnetic resonance spectroscopy (MRS) in
an effort to provide a better understanding of the role of brain gamma-aminobutyric acid (GABA) and glutamate in
the pathophysiology of OCD. We hypothesized that beyond the separate effects of these neurotransmitter systems,
a disruption in the balance between GABA and glutamate could be particularly relevant to OCD.
Methods: We obtained MRS measures of GABA and glutamate concentrations in the anterior cingulate cortex from
23 adult patients with OCD and 20 sex- and age-matched healthy community volunteers. Established clinical rating
scales were used to assess the severities of OCD, anxiety, and depression symptoms. Statistical analysis involved the
assessment of patient-control group differences in the individual measures of GABA and glutamate, as well as in the
ratio of the GABA to glutamate measures. Additionally, we explored whether differences in the MRS measures existed
between two subgroups of patients formed according to the severity of their OCD symptoms. Finally, we assessed the
relations of demographic and clinical variables to the MRS measures.
Results: Patients with OCD displayed a higher estimated GABA level and a higher GABA to glutamate ratio than healthy
participants, but no significant group differences were observed in the measure of glutamate. The MRS measures did not
vary by subgroup and showed no correlations with demographic and clinical variables.
Conclusions: These results indicate that GABA abnormalities within the anterior cingulate cortex contribute to the
pathophysiology of OCD. The results fail to provide evidence that glutamate abnormalities alone are involved in
adult OCD. Yet, it seems that a disruption in the balance between glutamate and GABA neurotransmission may
have a particularly important role to play in OCD pathophysiology.
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Background
Obsessive-compulsive disorder (OCD) is a psychiatric
disorder that afflicts approximately 1–3% of the general
population. This disorder is characterized by recurrent
intrusive thoughts (obsessions) and repetitive behaviors
or mental acts (compulsions), the latter typically per-
formed in response to obsessions or related anxiety [1].
OCD is a debilitating psychiatric disorder, ranked by the
World Health Organization as one of the 10 most disab-
ling illnesses in middle age due to loss of income and
diminished quality of life [2]. Current treatment of OCD
mainly consists of serotonergic medications, but a sub-
stantial portion of patients do no respond or respond
insufficiently to these medications which makes it im-
portant to investigate the role of other neurotransmitters
such as gamma-aminobutyric (GABA)and glutamate and
their role in OCD. [2]. Despite its impact on patients,
their families, and society as a whole, the pathophysi-
ology of OCD remains incompletely understood. Clinical
studies indicate that dysfunction of multiple neurotrans-
mitter systems contributes to the pathophysiology of
OCD. Initially, dysfunction of the central serotonergic
system has been implicated on the basis of the observed
therapeutic effects of selective serotonin reuptake inhibi-
tors on OCD symptoms [2, 3]. Subsequent studies using
positron emission tomography (PET) or single photon
emission computed tomography (SPECT) have implicated
additional neurotransmitters in the pathophysiology of
OCD. For example, it has been reported that patients with
OCD exhibit decreased striatal dopamine D2 receptor
binding compared to healthy controls [4], which indicates
that enhanced activity of the mesolimbic dopaminergic
system could be involved in OCD pathophysiology. Also,
patients with OCD have been characterized by increased
glucose metabolism in the orbitofrontal cortex [5, 6].
Moreover, studies using magnetic resonance spectroscopy
(MRS) have documented abnormalities in the levels of
neurotransmitter-related metabolites in several distinct
brain areas of patients with OCD [7], including decreased
glutamate-glutamine (Glx) concentrations in the anterior
cingulate cortex (ACC) [8] and increased gamma-
aminobutyric (GABA) concentrations in the medial pre-
frontal cortex [9]. These clinical studies have contributed
to the hypothesis that dysfunctions within cortico-striato-
thalamo-cortical (CSTC) brain circuitry are fundamental
to the pathophysiology of OCD.
These clinical studies have provided important clues
about the pathophysiology of OCD, but the observed
patient-control differences are usually small in size and
do not exhibit high levels of consistency across studies
[3, 10]. It seems that at least three factors make the
interpretation of results difficult. First, most studies have
examined only one neurotransmitter system, without
taking into account the dynamic interactions occurring
between different systems. It has been suggested, indeed,
that the balance between the excitatory neurotransmitter
glutamate and the inhibitor GABA is particularly relevant
to the integrity of brain and cognitive function in both
healthy and psychiatrically ill populations [11]. Second,
OCD is usually considered as a simple homogeneous diag-
nostic entity, and not as a complex and etiologically and
biologically hetergeneous disorder. Although no consen-
sus exists about the number, nature, and identification of
OCD subtypes, it would be informative to consider differ-
ent subgroups of patients formed according to a basic
clinical feature as illness severity or onset age. And third,
in MRS studies it can be difficult to obtain accurate
measures of the brain metabolites of interest due to a lack
of sensitivity to the low concentrations present in the spe-
cific brain region examined and to spectral overlap with
other signals and macromolecules. The present study was
designed to overcome these three limitations.
In this study, we utilized MRS in an effort to provide a
better understanding of the role of brain GABA and glu-
tamate in the pathophysiology of OCD. To achieve this
aim, we measured both GABA and Glx concentrations
in the ACC of patients with OCD and matched healthy
control participants. Moreover, we utilized the ratio of
GABA to Glx in an effort to assess the balance between
GABA and glutamate [12, 13]. As a key node in CSTC
circuit, the ACC was chosen as the region of interest
because this component of the CSTC seems especially
relevant to the clinical symptoms of OCD, as well as to
the disruption of cognitive and emotional functioning
often seen in affected patients [14]. Furthermore, deep
brain stimulation and ablative surgery of the ACC have
been found to alleviate symptoms of severe, treatment-
refractory cases of OCD [15], which exemplifies the
important role the ACC plays in OCD.
Additionally, we examined whether differences in our
measures of GABA and glutamate existed between two
subgroups of patients formed according to the severity
of their OCD symptoms. Finally, we employed a modi-
fied MRS technique to obtain reliable estimates of in
vivo GABA and glutamate concentrations. Assuming
that abnormalities of GABA and glutamate are indeed
linked to the pathophysiology of OCD, we hypothesized
that the patients with OCD and healthy controls would
differ in the measured levels of GABA and glutamate in
the ACC. If this hypothesis were to be confirmed,
MRS-based measures of brain GABA and glutamate
could potentially be developed into quantitative bio-
markers to aid the diagnosis or treatment of patients
with OCD.
According to our findings, the patients with OCD
showed a higher GABA+ level and a higher GABA+/
Glx ratio in the ACC compared to healthy control
participants, but no significant group differences were
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observed in the level of Glx, which confirmed our hy-
pothesis that the dynamic interplay between excitatory
glutamate and inhibitory GABA neurotransmission is
particularly involved.
Materials and methods
Participants
Study participants consisted of 23 patients with OCD and
20 healthy control (HC) participants between the ages of
24 and 50 years. Inclusion criteria for patients were: (1)
diagnosis of OCD made by a licensed psychologist or
psychiatrist on the basis of a clinical interview according
to DSM-IV-TR (Diagnostic and Statistical Manual of
Mental Disorders), (2) aged between 18 and 70 years, and
(3) no visible MRI structural abnormality. Exclusion were:
(1) diagnosis of intellectual disability or psychotic disorder,
and (2) contraindications to MRI scanning. All partici-
pants were asked to stop medication for 24 h before scan-
ning. Age- and sex-matched HCs who have no psychiatric
or neurological disease were recruited from the local
community through advertisements. Initially, the number
of study participants recruited was higher than the num-
ber indicated above, but one patient and two control
participants had to be excluded from analysis due to
excessive motion artifacts during MRI scanning.
Ethical statement
This study was approved by the ethics committee of
our hospital. All participants provided written in-
formed consent.
Clinical assessments and subgrouping
Two experienced clinicians assessed the severity of OCD,
anxiety, and depression of the patients using the Yale-
Brown Obsessive-Compulsive Scale (Y-BOCS) [16, 17],
Hamilton Anxiety Rating Scale (HAMA) [18], and the 17-
item Hamilton Depression Rating Scale (HAMD-17) [19].
As indicated in the Introduction, the patient group was
divided into two subgroups that differed from one another
in OCD symptom severity, as measured by using the total
Y-BOCS score: one subgroup of patients (n = 7) who
displayed relatively ‘moderate’ OCD symptoms (Y-BOCS
score < 25) and another subgroup (n = 16) who showed
‘severe’ symptoms (Y-BOCS score ≥ 25). Also, to explore
potential effects of serotonergic medication treatment on
our MRS measures, we compared one subgroup of pa-
tients (n = 5) who had never used serotonergic medication
for their OCD to another subgroup of patients (n = 18)
who had used medication (two types of selective serotonin
reuptake inhibitors for at least 3 months) but had failed to
show a clinical response.
MRI scans
All subjects were scanned using a 3.0 T MR scanner
(Ingenia, Philips, Best, The Netherlands), with a
fifteen-channel head coil. High-resolution 3D T1WI
MRI images of the brain were obtained with the
following parameters: repetition time/echo time (TR/
TE) = 8.1/3.7 ms; isotropic voxel size = 1 mm3 by using
the magnetization-prepared rapid gradient-echo se-
quence. The levels of GABA were measured using
the MEGA-PRESS sequence [20], with the following
parameters: TR/TE = 2000/68 ms, 14 ms editing pulses
alternating at 1.9 ppm (“Edit-On”) and 7.46 ppm
(“Edit-Off”) from the Larmor frequency of free water
to separate the GABA molecule from other chemi-
cals. The difference between the EDIT-ON and
EDIT-OFF spectra yields the peaks affected by the
editing pulses. The multiply optimized insensitive
suppression train method was used to suppress the
water signal and eight unsuppressed water averages
were applied to quantify the concentration of GABA.
The ACC was set as the volume of interest (VOI,
30 × 30 × 30 mm3, Fig. 1a-c), where the anterior grim
is bounded in the genu of the corpus callosum,
between the sulcus of the corpus callosum and the
cingulate sulcus.
Data processing
Due to fitting limitations, it’s unable to completely con-
trol for the potential contribution of macromolecules to
the MRS signal detected. Therefore, in the remaining
part of this paper, the signal detected at 3 ppm is labeled
as GABA+ instead of GABA, indicating the potential
contribution of these other compounds. The co-edited
Glx peak was seen at 3.75 ppm and did not interfere
with the GABA measurement. All GABA+ and Glx con-
centrations were quantified by using the MEGA-PRESS
specialized tool Gannet v2.0 [21]. Levels of GABA+ and
Glx were quantified by calculating the area under the
curve; GABA+ levels were gauged via a GABA+/Water
ratio. In Gannet, we used: (1) GannetLoad to process
time-domain MRS data; (2) GannetFit to model the edi-
ted spectrum; (3) GannetCoRegister to generate a mask
of the MRS voxel in T1-image space; (4) GannetSegment
to derive gray matter (GM), white matter (WM), and
cerebrospinal fluid (CSF) voxel fractions; and (5)
GannetQuantify to calculate tissue-corrected GABA and
Glx levels. A schematic picture of the data processing
procedure is presented in Fig. 2.
The ratios of the integrals of the GABA+ and water
signals, correcting for T1 and T2 relaxation times and
partial volume effects, were used to calculate the water-
scaled GABA+ concentration in mmol/L(mM) using the
following formula [22]:
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½GABA ¼ IG
IW
 H2O½   VISW
 f GM  RW GM þ f WM  RW WM þ f CSF  RW CSF
1− f CSFð Þ  RG
MMcor
where I
G
and I
W
are the fitting integrals of GABA+ (G),
and water (W) as determined by Gannet, [H2O] is the
pure water concentration (55,550mmol/L),VIS
w
is a fac-
tor accounting for MR water visibility and tissue proton
density (0.65), and f
GM
, f
WM
and f
CSF
are the fractions of
water attributable to GM, WM and CSF respectively
[22]. The relaxation attenuation factors are provided by
the equation RW y ¼ exp½−TE=T2W yð1− exp½−TR=T
1W y, where T1
W _ y
and T2
W _ y
are the T1 and T2 water
compartment relaxation times. Similarly, R
G
is the relax-
ation attenuation factor for GABA. The relaxation times
used were as follows: GM water: T1 = 1331ms, T2 = 110
ms; WM water: T1 = 832 ms, T2 = 79.6 ms; CSF: T1 =
3817 ms, T2 = 503 ms [23–25]; GABA: T1 = 1310ms,
T2 = 88ms [26, 27]. MMcor is a macromolecular correc-
tion factor (0.45) given by the fraction of the GABA+
peak that is considered to reflect GABA [28].Gannet
provides normalized residual fitting errors of GABA+,
which can be interpreted quantitatively to assess meas-
urement quality. Correspondingly, only spectra with a
fitting error of GABA+ below 10% were included in the
final analysis.
Each pixel in the 3D T1-weighted MRI images was
segmented into GM, WM, and CSF using SPM8 [29].
VOIs were coregistered to the anatomical images
using the “Re-creation of VOI” Matlab tool (as shown
in Fig. 1). Tissue GM fractions were obtained by cal-
culating the ratio of GM volume to the GM +WM
volumes in the VOIs. The concentrations of GABA in
the CSF were considered to be negligible [30].
Statistical analysis
Independent-samples t-tests were conducted to assess
mean differences between the OCD and HC groups in
age, GABA+, Glx, GABA+/Glx ratio, and tissue compos-
ition (except for the GM data, which were analyzed
using Mann-Whitney U tests). A chi-square test was
performed to evaluate differences in the proportions of
males and females between the OCD and HC groups.
Independent-samples t-test were also used for all
subgroup analyses within the patient group. Finally,
Pearson correlation coefficients were computed to ex-
plore whether our MRS measures correlated with demo-
graphic and clinical variables. The statistical significance
level was set at p < 0.05. SPSS v19.0 (IBM, Armonk, NY)
was used to analyze the data.
Results
Sample characteristics
Table 1 presents demographic and clinical characteristics
of the study participants. The OCD group did not differ
significantly from the HC group in terms of sex compos-
ition and age, but not for education. The patients showed
on average ‘severe’ OCD symptoms (mean Y-BOCS
score = 29.0, SD = 7.6), ranging from mild (Y-BOCS
score = 15) to extreme (Y-BOCS score = 40). The OCD
symptoms of most patients became evident in late adoles-
cence (mean age onset = 16.7, SD = 7.6). In addition to
OCD, the patients displayed ‘moderate’ and ‘mild’ symp-
toms of anxiety (mean HAMA score = 18.4, SD = 11.1)
Fig. 1 Position of MRS region of interest. A region of interest (ROI) with a size of 30 × 30 × 30mm3 was created over the anterior cingulate cortex
according to a high-resolution anatomic 3D T1WI MRI scan. The ROI is shown in (a) sagittal, (b) coronal, and (c) transversal orientations
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Fig. 2 Flowchart of the MEGA-PRESS MRS data processing procedure and representative results of each step. (a). Schematic picture of the MEGA-PRESS
MRS data processing procedure. (b) The processed GABA-edited difference spectrum (EDIT-OFF − EDIT-ON=DIFF) is the key output of the GannetLoad
module. This plot shows the spectrum before frequency and phase correction (above in green) and the spectrum after frequency and phase correction
(below in blue). (c) The Cr signal over the duration of the acquisition. The y-axis represents the frequency in ppm of the Cr signal. The spectra at each time
point are presented as a vertical stripe in the image (color-coded according to signal intensity), so the Cr signal appears as a ‘hot’ stripe running through
the image. In the lower half (POST), the result of frequency and phase correction is shown. (d) Model fitting of GABA+ and Glx spectrum
peaks, representing the GABA+ signal modeling (GannetFit output). The blue line represents the actual edited spectrum while the overlaid
red line is the model of best fit (using a simple Gaussian model by default). The residual is represented by the black curve below the
modeling plot. (e) The modeling of the signal against which GABA is quantified, using the same color scheme as in (d). In our experiment,
the unsuppressed water data were incorporated, so that the main spectrum is the water signal; the Cr signal is shown in an inset. The
water signal was modeled as a mixed Gaussian-Lorentzian and served as the reference for GABA quantification
Table 1 Demographic and Clinical Characteristics of the OCD and HC Groups
OCD (n = 23) HC (n = 20) t or χ2 df p
Mean age in years ± SD 31.7 ± 8.8 29.3 ± 5.6 1.061 37.846 0.295
Number of females/males 7/16 10/10 0.992 1 0.319
Mean age of OCD onset ± SD 17.2 ± 7.6 – –
Mean years of education ± SD 16.8 ± 3.7 12.7 ± 3.2 −3.828 41 0.000*
Mean Y-BOCS ± SD 29.0 ± 7.8 – –
Mean HAMA ± SD 18.4 ± 11.3 – –
Mean HAMD-17 ± SD 14.1 ± 8.7 – –
HAMA Hamilton Anxiety Rating Scale, HAMD-17 17-item Hamilton Depression Rating Scale HC healthy control, OCD obsessive-compulsive disorder, Yale-Brown
Obsessive-Compulsive Scale
*p < 0.05
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and depression (mean HAMD-17 score = 14.1, SD = 8.5).
Measures of tissue segmentation for both groups are pro-
vided in Table 2. There were no significant differences
between the OCD and HC groups regarding tissue com-
position in the ACC ROI (all p > 0.078).
Differences between OCD and HC groups
Significant differences between the OCD and HC groups
were observed in the level of GABA+ and the GABA+/
Glx ratio (As shown in Fig. 3 and Table 2). The OCD
group showed a higher level of GABA+ and a higher
GABA+/Glx ratio than the control group (Table 2), with
the size of the between-group differences being medium
(Cohen’s d = 0.64) and large (Cohen’s d = 0.84), respect-
ively. By contrast, no significant differences between the
OCD and HC groups were observed in the level of Glx.
Differences between OCD subgroups
Patients classified as having either relatively ‘moderate’
OCD or ‘severe’ OCD did not differ significantly from one
another on the MRS measures (Table 3). Similarly, patients
who had never received serotonergic medication treatment
Table 2 ACC Metabolite Levels and Tissue Composition in the OCD and HC groups
OCD (n = 23) HC (n = 20)
MRS metabolite Mean ± SD (iu+) Mean ± SD (iu) t(df) p
GABA+ 2.41 ± 0.59 2.10 ± 0.35 2.05 (41) 0.047*
Glx 2.10 ± 0.49 2.23 ± 0.38 −0.97 (41) 0.34
GABA+/Glx Ratio 1.18 ± 0.30 0.96 ± 0.22 2.70 (41) 0.01*
Tissue composition Mean Percentage ± SD Mean ± SD t(df) p
Cerebral spinal fluid 0.17 ± 0.02 0.16 ± 0.02 1.82 (41) 0.0781
Gray matter 0.52 ± 0.03 0.52 ± 0.03 / 0.752
White matter 0.31 ± 0.04 0.32 ± 0.03 1.59 (41) 0.3431
+iu, institutional units; ACC anterior cingulate cortex, GABA gamma-aminobutyric acid, Glx glutamate-glutamine, MRS magnetic resonance spectroscopy, HC healthy
control, OCD obsessive-compulsive disorder
*significant between-group difference (p < 0.05)
Fig. 3 Comparison between OCD and HC groups in a GABA+, b Glx and c GABA+/ Glx values. Significant differences between the OCD and HC
groups were observed in the level of GABA+ and the GABA+/Glx ratio. The OCD group showed a higher level of GABA+ and a higher GABA+/
Glx ratio than the control group. By contrast, no significant differences between the OCD and HC groups were observed in the level of Glx
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did not differ significantly in their levels of GABA+ and Glx
compared to patients who had a history of medication
treatment (Table 3). However, never medicated patients ex-
hibited a significantly larger GABA+/Glx ratio than patients
with a history of serotonergic medication treatment.
Correlations of MRS measures with demographic and
clinical variables
The MRS measures showed no significant correlations
with the demographic and clinical variables under
study (Table 4).
Discussion
In this study, patients with OCD showed a higher
GABA+ level and a higher GABA+/Glx ratio in the
ACC than healthy control participants, but no significant
group differences were observed in the level of Glx. The
former result supports the hypothesis that GABA abnor-
malities in the ACC are involved in the pathophysiology
of OCD. Furthermore, the higher GABA+/Glx ratio
observed in patients seems to confirm our hypothesis
that the dynamic interplay between excitatory glutamate
and inhibitory GABA neurotransmission is particularly
involved. Indeed, according to the obtained effect size
estimates, the diagnostic sensitivity of this ratio measure
was better than the measure of GABA alone. Finally, the
present results fail to support the hypothesis that ACC
glutamate abnormalities alone, as indexed by Glx levels,
play a significant role in OCD pathophysiology.
Our results are difficult to compare directly to previ-
ous studies on GABA levels in patients with OCD
because of methodological and patient sample differ-
ences. Furthermore, previous MRS studies focused on
the prefrontal cortex (PFC), and not on the ACC. For
example, Simpson et al. [31] found decreased GABA/W
levels in the medial PFC of adult patients with OCD
when compared to matched healthy participants. By
comparison, these researchers did not detect group dif-
ferences in GABA/W levels in the dorsolateral PFC.
Other studies have reported that plasma levels of GABA
are decreased in patients with OCD [32]. Despite
marked study differences, the present results also indi-
cate that GABA abnormalities within the CSTC circuit
are linked to OCD pathophysiology. An important goal
for further research is to determine whether our finding
of increased GABA levels in the ACC of patients with
OCD bears a relationship to decreased GABA levels in
the medial PFC reported in other studies.
The finding that the patients with OCD did not differ
from healthy participants in the level of Glx in the ACC
is also in agreement with previous studies [26, 29] and,
specifically, with the findings of Brennan et al. [33], who
reported the same finding in a patient sample similar to
our sample with respect to age, sex, and severity of OCD
symptoms. These researchers also question whether glu-
tamate abnormalities in the ACC are fundamental to
OCD pathophysiology, but leave room that these abnor-
malities could play a role in the early course of the
disorder [30] or in certain subtypes of OCD. Alterna-
tively, our study results indicate that glutamate abnor-
malities alone may not be directly involved, but that the
interaction of this excitatory neurotransmitter with
GABA could well have a significant pathophysiological
role to play in OCD.
The results of this study, however, should be qualified
because the observed GABA+ levels and GABA+/Glx ra-
tios neither differentiated patients with severe OCD
from patients with relatively moderate OCD nor corre-
lated with our continuous variables of clinical symptom
severity. Moreover, given the nonexperimental nature of
case-control studies, the possibility cannot be completely
excluded that the differences in the MRS measures be-
tween the patients with OCD and healthy participants
stem from factors other than the disease state of interest.
Table 3 MRS measures as a function of patient subgroups
MRS metabolite un-medicated OCD (n = 5) refractory OCD (n = 18) t(df ) p severe OCD (n = 16) moderate OCD (n = 7) t(df ) p
GABA+ 2.43 ± 0.23 2.40 ± 0.66 0.093 (21) 0.927 2.37 ± 0.61 2.48 ± 0.58 0.404 (21) 0.69
Glx 1.93 ± 0.42 2.15 ± 0.51 0.903 (21) 0.377 2.12 ± 0.56 2.06 ± 0.32 0.258 (21) 0.80
GABA+/Glx Ratio 1.31 ± 0.34 1.15 ± 0.29 1.116 (21) 0.277 1.16 ± 0.30 1.22 ± 0.32 0.436 (21) 0.667
ACC anterior cingulate cortex, GABA gamma-aminobutyric acid, Glx glutamate-glutamine, HC healthy control, MRS magnetic resonance spectroscopy, OCD
obsessive-compulsive disorder
Table 4 Correlations of MRS measures with demographic and clinical variables within the patient group (N = 23)
MRS metabolites Age Age of Onset Y-BOCS HAMA HAMD-17
GABA+ r(p) −0.264 (0.224) 0.307 (0.154) −0.307 (0.154) −0.033 (0.881) 0.001 (0.995)
Glx r(p) −0.144 (0.512) 0.309 (0.151) 0.007 (0.976) 0.01 (0.964) 0.071 (0.746)
GABA+/Glx Ratio r(p) −0.122 (0.578) −0.055 (0.805) − 0.267 (0.218) −0.071 (0.749) − 0.145 (0.509)
GABA gamma-aminobutyric acid, Glx glutamate-glutamine, HAMA Hamilton Anxiety Rating Scale,
HAMD-17 17-item Hamilton Depression Rating Scale, OCD obsessive-compulsive disorder
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Although both groups were similar to each other with re-
spect to sex and age, and serotonergic medication treat-
ment was associated with decreased, and not with
increased, GABA+/Glx ratios, the patients with OCD
could have differed from the community volunteers on nu-
merous other variables that potentially have affected the
MRS measures but that were not assessed and controlled
for in the study. For example, both groups could have dif-
fered from one another in cognitive function or socioeco-
nomic background. Moreover, the patients could have
differed from the community volunteers on variables that
are not directly linked to the pathophysiological process of
interest but that are likely to accompany the clinical diag-
nosis of OCD, such as treatment and hospitalization along
with the psychological and psychosocial consequences of
having received the formal diagnosis of the psychiatric dis-
order. In addition, SSRIs may take 1 week till they have a
noticeable effect and the effect should also not immedi-
ately decay if the patients do not use them for 24 h. We
cannot entirely exclude the SSRIs effect in the medicated
patients, which is a limitation [34, 35]. The healthy con-
trols were matched for age, gender, but not for edu-
cation and the small sample size is also a limitation
that should be considered in our future studies. Our
study results and conclusions, therefore, should be
regarded as tentative and preliminary until they have
been substantiated by further research.
Conclusions
This MRS study indicates that GABA abnormalities
within the ACC contribute to the pathophysiology of
OCD. Also, in line with previous MRS studies, the re-
sults fail to provide evidence that glutamate abnormal-
ities alone are involved in adult OCD. New tentative
evidence is provided, however, that a disruption in the
balance between GABA and glutamate neurotransmis-
sion has a particularly important role to play in OCD
pathophysiology. However, because of study limitations,
additional research is required to validate the present
observations and interpretations.
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